Gapping up
In reaction to strong earnings/guidance: HOFT +6.8%, GBX +5.6%, MY +4.8%, ISCA +2.9%, .
M&A news: INFA +5.2% (confirms agreement to be acquired by the Permira Funds and Canada Pension Plan Investment Board; transaction valued at approx $5.3 billion or $48.75 per share), FDX +4.5% (FedEx and TNT Express (TNTEY) agree on recommended all-cash public offer for all TNT Express shares for $4.8 billion), .
Select oil/gas related names showing strength: SSL +3.6%, STO +1.6%, BP +1.2%, RDS.A +1.1%, SDRL +0.8%
Other news: VBIV +20% (announced collaboration with Sanofi Pasteur (SNY) to to apply VBI's Lipid Particle Vaccine formulation technology to further the development of Sanofi Pasteur vaccine candidate), ONVO +13.5% (disclosed it entered into a research collaboration agreement with L'Oreal (LRLCY) USA products), BLDP +10.2% (announced that the world's first hydrogen fuel cell powered fixed rail electric tram was successfully demonstrated; production and testing facility of CSR Qingdao Sifang Company), CLVS +8.9% (received breakthrough therapy designation for Rucaparib for monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors), OCN +8% (co disclosed it amended its agreement with Home Loan Servicing Solutions (HLSS); New Residential Investment (NRZ) agreed to a multi-year extension of the servicing contracts with OCN), LSG +7.9% (announces record quarterly production in the first quarter of 2015), ARNA +7.8% (Arena Pharm and Eisai (ESALY) receives additional patent for Belviq), QEPM +7.2% (to be acquired in full by Tesoro Logistics LP (TLLP); consideration is valued at $17.09 per QEPM common unit), CYTX +5.3% (announces the European Commission has designated Cytori's ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma), AXTA +3.5% (announces that an affiliate of Berkshire Hathaway (BRK.B) has entered into a definitive stock purchase agreement with certain affiliates of The Carlyle Group (CG) for the purchase of a total of 20 mln of Axalta's common stock at $28.00 per share), SHPG +2.7% (announces clear regulatory path forward for SHP465, an investigational treatment for adults with ADHD), CLDX +0.9% (announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology)
Analyst comments: BIND +10.2% (initiated with an Outperform at Oppenheimer), CLDN +4.6% (initiated with a Buy at H.C. Wainwright), RYAAY +4% (upgraded to Overweight from Neutral at JP Morgan; also reported Mar traffic stats), SPLK +3.8% (upgraded to Overweight from Neutral at Piper Jaffray ), PAY +2.5% (upgraded to Buy from Hold at Stifel), DWRE +2.2% (added to Conviction Buy List at Goldman), CCL +1.1% (upgraded to Outperform from Market Perform at Wells Fargo ), TOT +1.1% ( upgraded to Outperform from Sector Perform at RBC Capital Mkts), JPM +0.8% (upgraded to Outperform from Mkt Perform at Bernstein), RL +0.7% (upgraded to Buy from Outperform at Credit Agricole)
In reaction to strong earnings/guidance: HOFT +6.8%, GBX +5.6%, MY +4.8%, ISCA +2.9%, .
M&A news: INFA +5.2% (confirms agreement to be acquired by the Permira Funds and Canada Pension Plan Investment Board; transaction valued at approx $5.3 billion or $48.75 per share), FDX +4.5% (FedEx and TNT Express (TNTEY) agree on recommended all-cash public offer for all TNT Express shares for $4.8 billion), .
Select oil/gas related names showing strength: SSL +3.6%, STO +1.6%, BP +1.2%, RDS.A +1.1%, SDRL +0.8%
Other news: VBIV +20% (announced collaboration with Sanofi Pasteur (SNY) to to apply VBI's Lipid Particle Vaccine formulation technology to further the development of Sanofi Pasteur vaccine candidate), ONVO +13.5% (disclosed it entered into a research collaboration agreement with L'Oreal (LRLCY) USA products), BLDP +10.2% (announced that the world's first hydrogen fuel cell powered fixed rail electric tram was successfully demonstrated; production and testing facility of CSR Qingdao Sifang Company), CLVS +8.9% (received breakthrough therapy designation for Rucaparib for monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors), OCN +8% (co disclosed it amended its agreement with Home Loan Servicing Solutions (HLSS); New Residential Investment (NRZ) agreed to a multi-year extension of the servicing contracts with OCN), LSG +7.9% (announces record quarterly production in the first quarter of 2015), ARNA +7.8% (Arena Pharm and Eisai (ESALY) receives additional patent for Belviq), QEPM +7.2% (to be acquired in full by Tesoro Logistics LP (TLLP); consideration is valued at $17.09 per QEPM common unit), CYTX +5.3% (announces the European Commission has designated Cytori's ECCS-50 cellular therapeutic as an orphan medicinal product for the treatment of scleroderma), AXTA +3.5% (announces that an affiliate of Berkshire Hathaway (BRK.B) has entered into a definitive stock purchase agreement with certain affiliates of The Carlyle Group (CG) for the purchase of a total of 20 mln of Axalta's common stock at $28.00 per share), SHPG +2.7% (announces clear regulatory path forward for SHP465, an investigational treatment for adults with ADHD), CLDX +0.9% (announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology)
Analyst comments: BIND +10.2% (initiated with an Outperform at Oppenheimer), CLDN +4.6% (initiated with a Buy at H.C. Wainwright), RYAAY +4% (upgraded to Overweight from Neutral at JP Morgan; also reported Mar traffic stats), SPLK +3.8% (upgraded to Overweight from Neutral at Piper Jaffray ), PAY +2.5% (upgraded to Buy from Hold at Stifel), DWRE +2.2% (added to Conviction Buy List at Goldman), CCL +1.1% (upgraded to Outperform from Market Perform at Wells Fargo ), TOT +1.1% ( upgraded to Outperform from Sector Perform at RBC Capital Mkts), JPM +0.8% (upgraded to Outperform from Mkt Perform at Bernstein), RL +0.7% (upgraded to Buy from Outperform at Credit Agricole)